Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments

BACKGROUND: Despite its efficacy, rational guidance for starting/stopping first-line biologic treatment in individual paediatric Crohn’s disease [CD] patients is needed. We assessed how serum immune profiles before and after first-line infliximab [FL-IFX] or conventional [CONV] induction therapy ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongsma, Maria M E, Costes, Lea M M, Tindemans, Irma, Cozijnsen, Martinus A, Raatgreep, Rolien (H) C, van Pieterson, Merel, Li, Yunlei, Escher, Johanna C, de Ridder, Lissy, Samsom, Janneke N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441564/
https://www.ncbi.nlm.nih.gov/pubmed/36934327
http://dx.doi.org/10.1093/ecco-jcc/jjad049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441564/
https://www.ncbi.nlm.nih.gov/pubmed/36934327
http://dx.doi.org/10.1093/ecco-jcc/jjad049

Ejemplares similares